Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and vibrators.
Popular Articles

Leading Medical Organizations Issue Revised Policy Statement On Learning Disabilities And Dyslexia
The American Academy of Ophthalmology announced that it has issued a revised policy statement on Learning Disabilities, Dyslexia, and Vision. The revised statement, which was issued jointly with the American Academy of Pediatrics (AAP), the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) and the American Association of Certified Orthoptists (AACO), expands upon the previous policy and includes extensive scientific references. The statement was also published today in Pediatrics, the journal of the AAP.
buy viagra
Legislation To Overhaul U.S. Foreign Aid Introduced
Senator John Kerry (D-Mass.), chairman of the Senate Foreign Relations Committee, and ranking member, Senator Richard Lugar (R-Ind.), on Tuesday "introduced a bill to overhaul the U.S. system for providing global development aid," the Boston Globe reports (Smith, 7/29). The legislation was also introduced by Senators Robert Menendez (D-NJ) and Bob Corker (R-Tenn.), according to a release from Menendez"s office (7/28).
News of the day
Uganda's Health Ministry Orders Investigations Into Deaths Of Patients Living With HIV
Uganda"s Health Ministry announced Monday it has ordered investigations into whether the deaths of 17 patients living with HIV in Northern Uganda were caused by their inability to get antiretroviral (ARV) drugs, the AP/mlive.com reports. According to Zainab Akol, manager of the ministry"s HIV/AIDS control program, the ministry is exploring "whether apart from the lack of ARVs, another disease like malaria or any epidemic could have contributed to the deaths," according to the news service.
Diagnostics

Endeavor Drug-Eluting Stent Is First To Receive CE Mark For Treating Acute Coronary Syndrome

Medtronic, Inc. (NYSE: MDT), announced that its Endeavor drug-eluting stent (DES) is the first and only coronary stent to have received CE (Conformité Européene) Mark approval for treating patients with acute coronary syndrome (ACS), which includes unstable angina and acute myocardial infarction (AMI), commonly known as heart attack. Medtronic is launching the unique ACS indication for the Endeavor DES today at PCR, a large and prestigious international meeting of interventional cardiologists. At this meeting today, Prof. Martin Rothman of the London Chest Hospital in the U.K. released positive new 12Ò€òmonth data from the international realÒ€òworld registry EÒ€òFive study (n=8,314) that show comparable outcomes for Endeavor DES patients with and without ACS . "Considering the distinctive safety record of the Endeavor stent, this indication for ACS makes perfect sense," said Prof. Rothman. "Results from the EÒ€òFive study support the use of the Endeavor stent in realÒ€òworld clinical practice, including ACS patients." Clinical research shows that ACS patients are at higher risk of stent thrombosis and mortality than nonÒ€òACS patients. ACS is a complex disease state for which drugÒ€òeluting stents are sometimes avoided due to concerns over longÒ€òterm safety and patient compliance with antiplatelet medication. "Of critical importance for safety, the biocompatibility of the Endeavor stent allows rapid and complete healing of the vessel wall," explained Sean Salmon, vice president and general manager of Medtronic CardioVascular"s Coronary and Peripheral business. "We believe that this healthy healing is the key to longÒ€òterm safety and efficacy." The EÒ€òFive study demonstrated no statistically significant difference on the primary endpoint - the rate of major adverse cardiac events (MACE) at one year - between ACS patients (7.8 percent, n=3,973) and nonÒ€òACS patients (7.2 percent, n=4,341). Rates of death, MI and late stent thrombosis (LST) at one year were similarly low and comparable between the two groups. - AllÒ€òcause mortality - 2.7% ACS, 2.2%, nonÒ€òACS - Cardiac death - 2.0% ACS, 1.5% nonÒ€òACS - MI - 1.8% ACS, 1.5% nonÒ€òACS - Cardiac death + MI - 3.4% ACS, 2.7% nonÒ€òACS - LST (ARC def/prob) - 0.5% ACS, 0.3% nonÒ€òACS Low and similar rates of standard efficacy measures were also observed, including target lesion revascularization (TLR), target vessel revascularization (TVR) and target vessel failure (TVF). On all these measures, there were no statistically significant differences between the ACS and nonÒ€òACS groups. Medtronic"s Endeavor stent originally received the CE mark in August 2005 as a treatment for coronary artery disease. This latest approval enables Medtronic to market the Endeavor DES specifically for ACS patients in the European Union, and all other countries that recognize the CE Mark. These countries do not include the United States or Japan, where the Endeavor DES is also commercially available but is not indicated for ACS patients. Medtronic, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009